e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
P. E. Postmus (Amsterdam, The Netherlands)
Source:
Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Session:
Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Session type:
Symposium
Number:
2902
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. E. Postmus (Amsterdam, The Netherlands). Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?. Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Is there any place for perioperative radiation therapy?
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007
The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment
Source: Annual Congress 2007 - Therapy of thoracic malignancies
Year: 2007
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer
Source: Annual Congress 2011 - General thoracic surgery II
Year: 2011
Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Comparison of quality of life in patients with non-small cell lung cancer treated by chemotherapy or radiotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 75s
Year: 2004
TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
The role of palliative radiotherapy in locally advanced non small cell lung cancer
Source: Annual Congress 2007 - Therapy of lung cancer
Year: 2007
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Chemotherapy in nonsmall cell lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=218
Year: 2001
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept